The researchers discovered a new drug for the treatment of Alzheimer's disease

The researchers discovered a new drug for the treatment of Alzheimer's disease

November 07, 2016 Source: Noble

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

US researchers reported on Wednesday that the new experimental treatment options for Alzheimer's disease have proven to be promising, with no harmful side effects.

A study based on a small sample of 32 people published in the journal Science Translational Medicine has led to two more extensive clinical trials and is currently undergoing research involving more than 3,000 subjects.

This treatment uses a compound called verubecestat developed by the American pharmaceutical company. It lowers the protein level called beta amyloid by blocking the BACE1 enzyme.

In people with Alzheimer's disease, protein aggregation forms plaques that damage the brain, affecting people's cognitive ability, especially memory. This enzyme plays a key role in the production of proteins.

Thirty-two patients who participated in the first clinical trial were diagnosed with mild to moderate Alzheimer's disease.

Pharmaceutical laboratories are working to develop compounds that block or even reverse the formation of these plaques.

To date, products for neutralizing BACEI enzymes have very harmful side effects such as liver damage or further neurodegeneration.

However, Dr. Matthew Kennedy of the Merck Research Laboratory in northeastern New Jersey said that verubecestat did not.

The researchers found that one or two doses of verubecestat compounds were sufficient to reduce protein levels without causing side effects.

Two Phase 3 clinical trials are currently underway and will be evaluated in July 2017 to evaluate the efficacy of verubecestat.

If the results are good, the compound can be sold in two or three years.

According to forecasts, the number of people who are over 80 years old in the baby boomer generation (the peak of the baby boom) in the United States may exceed 28 million by 2050.

According to the World Health Organization, 36 million people in the world suffer from some form of dementia, most of whom have Alzheimer's disease.

If no effective treatment is available in the next few years, this number is expected to double by 2030, exceeding 65.7 million, and if there is no effective treatment, it will double by 2050.

Engine Cylinder Liner

we are manufcatory and can supply the best price and good quality .

it is full range of CYLINDER LINER for the following type :

Engine Cylinder Liner,Engine Part Cylinder Liner,Diesel Engine Liner,Cylinder Liner For Ship,Cylinder Liner For Diesel Engine

ZhouShan HeCheng Machinery Co., LTD. , https://www.hcmarineparts.com